EP2591357A4 - Lung cancer biomarkers and uses thereof - Google Patents
Lung cancer biomarkers and uses thereofInfo
- Publication number
- EP2591357A4 EP2591357A4 EP11804482.5A EP11804482A EP2591357A4 EP 2591357 A4 EP2591357 A4 EP 2591357A4 EP 11804482 A EP11804482 A EP 11804482A EP 2591357 A4 EP2591357 A4 EP 2591357A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- lung cancer
- cancer biomarkers
- biomarkers
- lung
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/30—Unsupervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B99/00—Subject matter not provided for in other groups of this subclass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36312210P | 2010-07-09 | 2010-07-09 | |
US201161444947P | 2011-02-21 | 2011-02-21 | |
PCT/US2011/043595 WO2012006632A2 (en) | 2010-07-09 | 2011-07-11 | Lung cancer biomarkers and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2591357A2 EP2591357A2 (en) | 2013-05-15 |
EP2591357A4 true EP2591357A4 (en) | 2014-01-01 |
Family
ID=45441874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11804482.5A Withdrawn EP2591357A4 (en) | 2010-07-09 | 2011-07-11 | Lung cancer biomarkers and uses thereof |
Country Status (12)
Country | Link |
---|---|
US (3) | US20130116150A1 (en) |
EP (1) | EP2591357A4 (en) |
JP (1) | JP5905003B2 (en) |
KR (1) | KR101870123B1 (en) |
CN (2) | CN102985819B (en) |
AU (1) | AU2011274422B2 (en) |
BR (1) | BR112012032537B8 (en) |
CA (1) | CA2801110C (en) |
IL (1) | IL223295A (en) |
MX (2) | MX2012014268A (en) |
SG (2) | SG10201508656VA (en) |
WO (1) | WO2012006632A2 (en) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4991847B2 (en) * | 2006-05-09 | 2012-08-01 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | Dissolved protein arthritis marker |
CN101952313B (en) | 2007-11-27 | 2017-12-15 | 不列颠哥伦比亚大学 | 14 33 η antibody and its for diagnose and treatment of arthritis purposes |
US8285719B1 (en) | 2008-08-08 | 2012-10-09 | The Research Foundation Of State University Of New York | System and method for probabilistic relational clustering |
US10359425B2 (en) * | 2008-09-09 | 2019-07-23 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
US20100221752A2 (en) * | 2008-10-06 | 2010-09-02 | Somalogic, Inc. | Ovarian Cancer Biomarkers and Uses Thereof |
US9495515B1 (en) | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
KR101894597B1 (en) | 2009-03-11 | 2018-10-04 | 오거렉스 라이프 사이언시스 코포레이션 | Compositions and methods for characterizing arthritic conditions |
CA2801110C (en) | 2010-07-09 | 2021-10-05 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
CA2804857C (en) | 2010-08-13 | 2021-07-06 | Somalogic, Inc. | Pancreatic cancer biomarkers and uses thereof |
US20140235487A1 (en) * | 2010-11-12 | 2014-08-21 | William Marsh Rice University | Oral cancer risk scoring |
US10132806B2 (en) | 2011-10-21 | 2018-11-20 | Augurex Life Sciences Corp. | Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis |
US20130282390A1 (en) * | 2012-04-20 | 2013-10-24 | International Business Machines Corporation | Combining knowledge and data driven insights for identifying risk factors in healthcare |
US20150088430A1 (en) * | 2012-04-26 | 2015-03-26 | Allegro Diagnostics Corp | Methods for evaluating lung cancer status |
JP6022285B2 (en) * | 2012-09-28 | 2016-11-09 | シスメックス株式会社 | Specimen storage device, specimen storage method, and specimen inspection system |
EP2912182B1 (en) | 2012-10-23 | 2021-12-08 | Caris Science, Inc. | Aptamers and uses thereof |
US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
CN104812913B (en) | 2012-11-07 | 2019-03-15 | 私募蛋白质体公司 | Chronic Obstructive Pulmonary Disease (COPD) biomarker and application thereof |
AU2013361323B2 (en) | 2012-12-19 | 2018-09-06 | Caris Science, Inc. | Compositions and methods for aptamer screening |
EP3626308A1 (en) | 2013-03-14 | 2020-03-25 | Veracyte, Inc. | Methods for evaluating copd status |
EP3296747B1 (en) | 2013-03-15 | 2020-01-08 | Somalogic, Inc. | Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof |
WO2014153327A1 (en) | 2013-03-18 | 2014-09-25 | Barbeau James M | Methods to determine carcinogenesis, identify markers for early cancer diagnosis and identify targets of therapy |
US10501803B2 (en) * | 2013-05-21 | 2019-12-10 | Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. | Isoforms of GATA6 and NKX2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy |
KR101552014B1 (en) | 2013-10-11 | 2015-09-09 | 인제대학교 산학협력단 | Novel use of NIR for diagnosing lung cancer |
WO2015066564A1 (en) * | 2013-10-31 | 2015-05-07 | Cancer Prevention And Cure, Ltd. | Methods of identification and diagnosis of lung diseases using classification systems and kits thereof |
KR102310799B1 (en) * | 2013-11-07 | 2021-10-12 | 미디얼 리서치 리미티드 | Methods and systems of evaluating a risk of lung cancer |
JP6703479B2 (en) * | 2013-12-16 | 2020-06-03 | フィリップ モリス プロダクツ エス アー | System and method for predicting individual smoking status |
RU2538625C1 (en) * | 2014-01-20 | 2015-01-10 | Денис Николаевич Бахмутов | Diagnostic technique for cancer |
WO2015164617A1 (en) | 2014-04-24 | 2015-10-29 | Somalogic, Inc. | Tuberculosis biomarkers in urine and uses thereof |
WO2015164616A1 (en) | 2014-04-24 | 2015-10-29 | Somalogic, Inc. | Biomarkers for detection of tuberculosis |
WO2015164772A1 (en) * | 2014-04-25 | 2015-10-29 | Rush University Medical Center | Circulating insulin-like growth factor (igf)-associated proteins for the detection of lung cancer |
CN114807368A (en) * | 2014-07-14 | 2022-07-29 | 威拉赛特公司 | Methods for assessing lung cancer status |
AU2014407088B2 (en) | 2014-09-26 | 2021-09-23 | Somalogic Operating Co., Inc. | Cardiovascular risk event prediction and uses thereof |
CN107206043A (en) | 2014-11-05 | 2017-09-26 | 维拉赛特股份有限公司 | The system and method for diagnosing idiopathic pulmonary fibrosis on transbronchial biopsy using machine learning and higher-dimension transcript data |
WO2016123058A1 (en) | 2015-01-27 | 2016-08-04 | Somalogic, Inc. | Biomarkers for detection of tuberculosis risk |
US20180356419A1 (en) | 2015-05-08 | 2018-12-13 | Somalogic, Inc. | Biomarkers for detection of tuberculosis risk |
EP3347720A1 (en) * | 2015-09-09 | 2018-07-18 | Somalogic, Inc. | Methods for developing personalized drug treatment plans and targeted drug development based on proteomic profiles |
CN108026584B (en) * | 2015-09-11 | 2021-12-10 | 适体科学株式会社 | Protein biomarker panel for diagnosing non-small cell lung cancer and non-small cell lung cancer diagnosis method using same |
US10546650B2 (en) | 2015-10-23 | 2020-01-28 | Google Llc | Neural network for processing aptamer data |
MX2018009170A (en) | 2016-02-08 | 2018-11-19 | Somalogic Inc | Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof. |
JP6041331B1 (en) * | 2016-02-26 | 2016-12-07 | 国立大学法人山口大学 | Information processing apparatus, information processing program, and information processing method |
JP6889428B2 (en) * | 2016-02-26 | 2021-06-18 | 国立大学法人山口大学 | Information processing equipment, information processing programs, and information processing methods |
CN107435062B (en) * | 2016-05-25 | 2020-10-20 | 上海伯豪医学检验所有限公司 | Peripheral blood gene marker for discriminating benign and malignant pulmonary nodules and application thereof |
JP7058264B2 (en) * | 2016-06-08 | 2022-04-21 | リサーチ ディヴェロプメント ファウンデーション | Systems and methods for automatic feature analysis and risk assessment of coronary plaques using intravascular optical coherence tomography |
BR112018076528A2 (en) * | 2016-06-21 | 2019-04-02 | The Wistar Institute Of Anatomy And Biology | compositions and methods for diagnosing lung cancers using gene expression profiles |
EP3629904A4 (en) * | 2017-06-02 | 2021-03-31 | Veracyte, Inc. | Methods and systems for identifying or monitoring lung disease |
CN109470855B (en) * | 2017-09-08 | 2022-02-11 | 广州市丹蓝生物科技有限公司 | Protein chip and kit for early diagnosis of lung cancer |
KR102028967B1 (en) | 2017-12-28 | 2019-10-07 | 한국원자력의학원 | Biomarker for lung cancer metastasis diagnosis comprising rip1 and use thereof |
US20210140977A1 (en) | 2018-04-16 | 2021-05-13 | University Of Cape Town | A three-protein proteomic biomarker for prospective determination of risk for development of active tuberculosis |
CA3104041A1 (en) * | 2018-06-22 | 2019-12-26 | Somalogic, Inc. | Improved proteomic multiplex assays |
WO2020018005A1 (en) * | 2018-07-17 | 2020-01-23 | Limited Liability Company "Gero" | Devices, methods, compositions and systems for the treatment of aging and age- related disorders |
KR102216645B1 (en) * | 2018-10-29 | 2021-02-17 | 사회복지법인 삼성생명공익재단 | Biomarker panel for determination of molecular subtype of lung cancer and uses thereof |
KR20210089178A (en) * | 2018-10-30 | 2021-07-15 | 소마로직, 인크. | How to evaluate sample quality |
CN109470859A (en) * | 2018-11-04 | 2019-03-15 | 华东医院 | A kind of excretion body protein is as identifying the good pernicious marker of Lung neoplasm and its application |
EP3671210A1 (en) * | 2018-12-21 | 2020-06-24 | Biosystems International KFT | Lung cancer protein epitomic biomarkers |
WO2020243574A1 (en) * | 2019-05-31 | 2020-12-03 | Delphinus Medical Technologies, Inc. | Systems and methods for interactive lesion characterization |
US20210027890A1 (en) * | 2019-07-24 | 2021-01-28 | ConnSante BioTech, Inc. | Detecting, evaluating and predicting system for cancer risk |
CA3151482A1 (en) | 2019-09-03 | 2021-03-11 | Somalogic Operating Co., Inc. | Cardiovascular risk event prediction and uses thereof |
JP2023509677A (en) | 2020-01-10 | 2023-03-09 | ソマロジック オペレーティング カンパニー インコーポレイテッド | Methods for determining impaired glucose tolerance |
GB2603051B (en) | 2020-01-30 | 2023-04-26 | Prognomiq Inc | Lung biomarkers and methods of use thereof |
CN115066616A (en) | 2020-02-10 | 2022-09-16 | 私募蛋白质体操作有限公司 | Non-alcoholic steatohepatitis (NASH) biomarker and application thereof |
KR102260915B1 (en) | 2020-02-19 | 2021-06-04 | 한국원자력의학원 | Biomaker for predictiong prognosis of lung cancer after radiotherapy |
CN111876478A (en) * | 2020-04-28 | 2020-11-03 | 中国科学院微生物研究所 | Pulmonary nodule diagnostic marker and application |
US20230304099A1 (en) * | 2020-08-14 | 2023-09-28 | The Medical College Of Wisconsin, Inc. | Gene Expression Signature for Predicting Immunotherapy Response and Methods of Use |
KR20230080442A (en) * | 2020-10-02 | 2023-06-07 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Methods for Detection and Treatment of Lung Cancer |
WO2022073502A1 (en) * | 2020-10-10 | 2022-04-14 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | Use of biomarker in preparation of lung cancer detection reagent and related method |
AU2021364805A1 (en) | 2020-10-20 | 2023-05-18 | Somalogic Operating Co., Inc. | Cardiovascular event risk prediction |
GB2607436A (en) * | 2021-03-31 | 2022-12-07 | Prognomiq Inc | Multi-omic assessment |
WO2023141248A1 (en) | 2022-01-21 | 2023-07-27 | Somalogic Operating Co., Inc. | Methods for sample quality assessment |
WO2023211769A1 (en) | 2022-04-24 | 2023-11-02 | Somalogic Operating Co., Inc. | Methods for sample quality assessment |
WO2023211771A1 (en) | 2022-04-24 | 2023-11-02 | Somalogic Operating Co., Inc. | Methods for sample quality assessment |
WO2023211770A1 (en) | 2022-04-24 | 2023-11-02 | Somalogic Operating Co., Inc. | Methods for sample quality assessment |
WO2023211773A1 (en) | 2022-04-24 | 2023-11-02 | Somalogic Operating Co., Inc. | Methods for sample quality assessment |
WO2023244582A1 (en) * | 2022-06-13 | 2023-12-21 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Lung cancer-related biomarkers and methods of using the same |
WO2024010854A1 (en) * | 2022-07-07 | 2024-01-11 | Diagnose Early, Inc. | Rapid generation of breath-based health reports and systems for use in the same |
WO2024015485A1 (en) | 2022-07-14 | 2024-01-18 | Somalogic Operating Co., Inc. | Methods of assessing dementia risk |
WO2024015486A1 (en) | 2022-07-14 | 2024-01-18 | Somalogic Operating Co., Inc. | Methods for sample quality assessment |
WO2024064322A2 (en) | 2022-09-23 | 2024-03-28 | Somalogic Operating Co., Inc. | Methods of assessing tobacco use status |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002086443A2 (en) * | 2001-04-18 | 2002-10-31 | Protein Design Labs, Inc | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
US20100070191A1 (en) * | 2008-09-09 | 2010-03-18 | Somalogic, Inc. | Lung Cancer Biomarkers and Uses Thereof |
Family Cites Families (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
US20040254101A1 (en) | 1995-06-06 | 2004-12-16 | Human Genome Sciences, Inc. | Colon specific gene and protein and cancer |
US6004267A (en) | 1997-03-07 | 1999-12-21 | University Of Florida | Method for diagnosing and staging prostate cancer |
WO2000052204A2 (en) | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
KR100768985B1 (en) | 1999-09-10 | 2007-10-22 | 무라마쯔 다카시 | Early cancer tumor marker |
EP1472352A4 (en) | 2000-03-06 | 2005-10-12 | Smithkline Beecham Corp | Novel compounds |
US20030224501A1 (en) | 2000-03-17 | 2003-12-04 | Young Paul E. | Bone morphogenic protein polynucleotides, polypeptides, and antibodies |
US6596503B1 (en) | 2000-08-18 | 2003-07-22 | East Carolina University | Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof |
US6631330B1 (en) | 2000-08-21 | 2003-10-07 | Assistance Publique-Hopitaux De Paris (Ap-Hp) | Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers |
US6576423B2 (en) | 2000-12-08 | 2003-06-10 | The Board Of Regents Of The University Of Nebraska | Specific mucin expression as a marker for pancreatic cancer |
US7189507B2 (en) | 2001-06-18 | 2007-03-13 | Pdl Biopharma, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
US7622260B2 (en) | 2001-09-05 | 2009-11-24 | The Brigham And Women's Hospital, Inc. | Diagnostic and prognostic tests |
US20040009489A1 (en) | 2001-09-28 | 2004-01-15 | Golub Todd R. | Classification of lung carcinomas using gene expression analysis |
US20040241653A1 (en) * | 2001-12-31 | 2004-12-02 | Elena Feinstein | Methods for identifying marker genes for cancer |
EP2241636A1 (en) | 2002-03-13 | 2010-10-20 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
US20050260639A1 (en) | 2002-09-30 | 2005-11-24 | Oncotherapy Science, Inc. | Method for diagnosing pancreatic cancer |
CA2500472A1 (en) | 2002-09-30 | 2004-04-15 | Oncotherapy Science, Inc. | Genes and polypeptides relating to human pancreatic cancers |
US8008003B2 (en) | 2002-11-15 | 2011-08-30 | Genomic Health, Inc. | Gene expression profiling of EGFR positive cancer |
US20040219572A1 (en) | 2002-12-17 | 2004-11-04 | Jie Chen | Specific markers for pancreatic cancer |
WO2004061410A2 (en) | 2002-12-18 | 2004-07-22 | Ciphergen Biosystems, Inc. | Serum biomarkers in lung cancer |
US20050181375A1 (en) | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
AU2003900747A0 (en) | 2003-02-18 | 2003-03-06 | Garvan Institute Of Medical Research | Diagnosis and treatment of pancreatic cancer |
DE602004017426D1 (en) | 2003-02-20 | 2008-12-11 | Genomic Health Inc | USE OF INTRONIC RNA SEQUENCES FOR THE QUANTIFICATION OF GENE EXPRESSION |
CA2516591A1 (en) | 2003-02-26 | 2004-09-10 | Mount Sinai Hospital | Multiple marker assay for detection of ovarian cancer |
US20050095611A1 (en) | 2003-05-02 | 2005-05-05 | Chan Daniel W. | Identification of biomarkers for detecting pancreatic cancer |
CN1455257A (en) * | 2003-05-23 | 2003-11-12 | 北京师范大学 | Method of diagnosing lung cancer using surface modified protein chip |
US20060019256A1 (en) | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
ES2609234T3 (en) | 2003-06-24 | 2017-04-19 | Genomic Health, Inc. | Prediction of the probability of cancer recurrence |
EP1644858B1 (en) | 2003-07-10 | 2017-12-06 | Genomic Health, Inc. | Expression profile algorithm and test for cancer prognosis |
US20050069963A1 (en) | 2003-08-15 | 2005-03-31 | Lokshin Anna E. | Multifactorial assay for cancer detection |
US7807392B1 (en) | 2003-09-15 | 2010-10-05 | Celera Corporation | Lung disease targets and uses thereof |
US20070148648A1 (en) | 2003-11-04 | 2007-06-28 | Martin Dugas | Method for distinguishing who classified aml subtypes |
EP2026071B1 (en) | 2004-02-19 | 2013-07-31 | Yale University | Identification of cancer protein biomarkers using proteomic techniques |
JP2007527247A (en) | 2004-03-05 | 2007-09-27 | ロゼッタ インファーマティクス エルエルシー | Classification of breast cancer patients using a combination of clinical criteria and informative gene sets |
EP2163650B1 (en) | 2004-04-09 | 2015-08-05 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
ES2367311T3 (en) | 2004-04-15 | 2011-11-02 | University Of Florida Research Foundation, Inc. | MAP-2 PROTEOLYTIC DEGRADATION PRODUCTS AS DIAGNOSTIC BIOMARCATORS FOR NEURAL INJURIES. |
EP1743031A4 (en) | 2004-04-26 | 2008-05-28 | Childrens Medical Center | Platelet biomarkers for the detection of disease |
US20070275422A1 (en) | 2004-07-26 | 2007-11-29 | The Board Of Trustees Of The Leland Stanford Jr. U | Methods and Compositions for Detecting Pancreatic Disease |
WO2006022895A2 (en) | 2004-08-02 | 2006-03-02 | Children's Medical Center Corporation | Platelet biomarkers for cancer |
EP1787122B1 (en) | 2004-08-10 | 2010-10-06 | Oncotherapy Science, Inc. | NON-SMALL CELL LUNG CANCER-RELATED GENE, ANLN, AND ITS INTERACTIONS WITH RhoA |
JP2006053113A (en) * | 2004-08-16 | 2006-02-23 | Medical Proteoscope Co Ltd | Method and kit for diagnosing pulmonary adenocarcinoma lymph node metastasis |
DK1836629T3 (en) | 2004-11-05 | 2020-05-18 | Genomic Health Inc | PREDICTION OF RESPONSE TO CHEMOTHERAPY USING MARKERS FOR GENEPRESSION |
AU2005304878B2 (en) | 2004-11-05 | 2010-07-08 | Genomic Health, Inc. | Molecular indicators of breast cancer prognosis and prediction of treatment response |
US7862995B2 (en) | 2004-12-10 | 2011-01-04 | Targeted Molecular Diagnostics | Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor |
US8632983B2 (en) | 2005-04-15 | 2014-01-21 | Van Andel Research Institute | Biomarkers for pancreatic cancer and diagnostic methods |
WO2006135886A2 (en) | 2005-06-13 | 2006-12-21 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
US20090005268A1 (en) | 2005-07-18 | 2009-01-01 | Epigenomics Ag | Compositions and Methods for Cancer Diagnostics Comprising Pan-Cancer Markers |
US7521195B1 (en) | 2005-07-21 | 2009-04-21 | Celera Corporation | Lung disease targets and uses thereof |
EP2295571A1 (en) | 2005-07-27 | 2011-03-16 | Oncotherapy Science, Inc. | Method of diagnosing small cell lung cancer |
EP1937837A2 (en) | 2005-07-29 | 2008-07-02 | Siemens Healthcare Diagnostics Inc. | Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies |
US7582441B1 (en) | 2005-10-17 | 2009-09-01 | Celera Corporation | Methods and compositions for treating and diagnosing disease |
EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
US8329408B2 (en) | 2005-10-31 | 2012-12-11 | Bayer Healthcare Llc | Methods for prognosis and monitoring cancer therapy |
CA2632190A1 (en) * | 2005-11-10 | 2007-07-12 | University Of Kentucky | Lung cancer diagnostic assay |
US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
WO2007076439A2 (en) | 2005-12-22 | 2007-07-05 | Abbott Laboratories | Methods and marker combinations for screening for predisposition to lung cancer |
NZ593228A (en) | 2006-01-11 | 2012-10-26 | Genomic Health Inc | Gene expression markers (inhba) for colorectal cancer prognosis |
MX2008009592A (en) | 2006-01-27 | 2008-09-08 | Tripath Imaging Inc | Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor. |
WO2007092433A2 (en) | 2006-02-06 | 2007-08-16 | Tethys Bioscience, Inc. | Osteoporosis associated markers and methods of use thereof |
WO2007109571A2 (en) | 2006-03-17 | 2007-09-27 | Prometheus Laboratories, Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
US7888019B2 (en) | 2006-03-31 | 2011-02-15 | Genomic Health, Inc. | Genes involved estrogen metabolism |
ES2550004T3 (en) | 2006-04-04 | 2015-11-03 | Singulex, Inc. | High sensitivity system and troponin analysis methods |
WO2007146229A2 (en) | 2006-06-07 | 2007-12-21 | Tethys Bioscience, Inc. | Markers associated with arteriovascular events and methods of use thereof |
WO2008003024A2 (en) | 2006-06-28 | 2008-01-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Method and composition for diagnosing endometrial cancer |
EP2090665A2 (en) | 2006-10-20 | 2009-08-19 | Exiqon A/S | Novel human microRNAs associated with cancer |
WO2008063413A2 (en) * | 2006-11-13 | 2008-05-29 | Source Precision Medicine, Inc. | Gene expression profiling for identification, monitoring, and treatment of lung cancer |
US7964356B2 (en) | 2007-01-16 | 2011-06-21 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
US7947447B2 (en) * | 2007-01-16 | 2011-05-24 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
KR100846354B1 (en) * | 2007-03-21 | 2008-07-15 | (주) 프로탄바이오 | Diagnostic biomarker for lung adenocarcinoma isolated from serum glycoproteins |
JP6115801B2 (en) | 2007-03-27 | 2017-04-19 | イミュノヴィア・アーベー | Protein signature / marker for adenocarcinoma detection |
RU2376372C2 (en) | 2007-04-03 | 2009-12-20 | Государственное учреждение Научно-исследовательский институт медицинской генетики Томского научного центра Сибирского отделения Российской академии медицинских наук | Method for genetic diagnostics of susceptibility to cardiovascular diseases |
CA2681667A1 (en) | 2007-05-18 | 2008-11-27 | Duke University | Serum biomarkers for the early detection of lung cancer |
CA2688299A1 (en) | 2007-05-29 | 2008-12-18 | President And Fellows Of Harvard College | Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof |
DK2069529T3 (en) * | 2007-07-17 | 2013-04-15 | Somalogic Inc | Process for generating aptamers with improved dissociation rates |
EP2019318A1 (en) | 2007-07-27 | 2009-01-28 | Erasmus University Medical Center Rotterdam | Protein markers for cardiovascular events |
GB0717637D0 (en) | 2007-09-10 | 2007-10-17 | Univ Leiden | Future cardiac event biomarkers |
WO2009036123A1 (en) * | 2007-09-11 | 2009-03-19 | Cancer Prevention And Cure, Ltd. | Method of identifying biomarkers in human serum indicative of pathologies of human lung tissues |
US8541183B2 (en) * | 2007-09-11 | 2013-09-24 | Cancer Prevention And Cure, Ltd. | Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof |
US20100267041A1 (en) | 2007-09-14 | 2010-10-21 | Predictive Biosciences, Inc. | Serial analysis of biomarkers for disease diagnosis |
AU2008302526A1 (en) * | 2007-09-18 | 2009-03-26 | Board Of Regents Of The University Of Texas System | Detection of saliva proteins modulated secondary to ductal carcinoma in situ of the breast |
US7892760B2 (en) | 2007-11-19 | 2011-02-22 | Celera Corporation | Lung cancer markers, and uses thereof |
WO2009091581A2 (en) | 2008-01-18 | 2009-07-23 | Vatrix Medical, Inc. | Diagnostic biomarkers for vascular aneurysm |
GB0803192D0 (en) | 2008-02-22 | 2008-04-02 | Mubio Products Bv | SCLC biomarker panel |
WO2009114836A1 (en) | 2008-03-14 | 2009-09-17 | Genomic Health, Inc. | Gene expression markers for prediction of patient response to chemotherapy |
WO2010030697A1 (en) | 2008-09-09 | 2010-03-18 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
US20120143805A1 (en) | 2008-09-09 | 2012-06-07 | Somalogic, Inc. | Cancer Biomarkers and Uses Thereof |
US20100221752A2 (en) | 2008-10-06 | 2010-09-02 | Somalogic, Inc. | Ovarian Cancer Biomarkers and Uses Thereof |
US20120165217A1 (en) | 2008-10-06 | 2012-06-28 | Somalogic, Inc. | Cancer Biomarkers and Uses Thereof |
RU2545757C2 (en) | 2008-10-30 | 2015-04-10 | Сантр Де Решерш Пюблик Де Ля Сантэ | Biomarkers |
GB2477705B (en) | 2008-11-17 | 2014-04-23 | Veracyte Inc | Methods and compositions of molecular profiling for disease diagnostics |
EP2366162A1 (en) | 2008-11-18 | 2011-09-21 | Collabrx, Inc. | Individualized cancer treatment |
CA2745961A1 (en) | 2008-12-04 | 2010-06-10 | The Regents Of The University Of California | Materials and methods for determining diagnosis and prognosis of prostate cancer |
AU2010259022B2 (en) | 2009-06-08 | 2016-05-12 | Singulex, Inc. | Highly sensitive biomarker panels |
ES2623633T3 (en) | 2009-06-09 | 2017-07-11 | Gendiag.Exe, S.L. | Risk markers for cardiovascular disease |
EA201270020A1 (en) | 2009-06-15 | 2012-07-30 | Кардиодкс, Инк. | DETERMINATION OF THE RISK OF DEVELOPMENT OF ATHEROSCLEROTIC HEART DISEASE |
WO2011022552A2 (en) | 2009-08-19 | 2011-02-24 | The Cleveland Clinic Foundation | Marker Detection for Characterizing the Risk of Cardiovascular Disease or Complications Thereof |
WO2011035433A1 (en) * | 2009-09-23 | 2011-03-31 | University Health Network | Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers |
WO2011050328A2 (en) | 2009-10-22 | 2011-04-28 | The Regents Of The University Of California | Assessment of solid tumor burden |
EP2494364A1 (en) | 2009-10-29 | 2012-09-05 | Tethys Bioscience, Inc. | Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes |
AU2010326066A1 (en) | 2009-12-01 | 2012-06-21 | Compendia Bioscience, Inc. | Classification of cancers |
EP2510116A2 (en) | 2009-12-09 | 2012-10-17 | Aviir, Inc. | Biomarker assay for diagnosis and classification of cardiovascular disease |
WO2011094483A2 (en) | 2010-01-29 | 2011-08-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Immune gene signatures in cancer |
US9624547B2 (en) | 2010-02-10 | 2017-04-18 | The Regents Of The University Of California | Salivary transcriptomic and proteomic biomarkers for breast cancer detection |
US9128101B2 (en) | 2010-03-01 | 2015-09-08 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarkers for theranostics |
JP2013526852A (en) | 2010-04-06 | 2013-06-27 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス | Circulating biomarkers for disease |
US20110256545A1 (en) * | 2010-04-14 | 2011-10-20 | Nancy Lan Guo | mRNA expression-based prognostic gene signature for non-small cell lung cancer |
CA2801110C (en) | 2010-07-09 | 2021-10-05 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
CA2804857C (en) | 2010-08-13 | 2021-07-06 | Somalogic, Inc. | Pancreatic cancer biomarkers and uses thereof |
EP2622104A4 (en) | 2010-09-27 | 2015-04-15 | Somalogic Inc | Mesothelioma biomarkers and uses thereof |
CN103703371A (en) * | 2011-04-29 | 2014-04-02 | 癌症预防和治疗有限公司 | Methods of identification and diagnosis of lung diseases using classification systems and kits thereof |
SG10201607331WA (en) | 2011-09-30 | 2016-11-29 | Somalogic Inc | Cardiovascular risk event prediction and uses thereof |
IN2014CN01787A (en) | 2011-10-24 | 2015-05-29 | Somalogic Inc | |
CN104812913B (en) | 2012-11-07 | 2019-03-15 | 私募蛋白质体公司 | Chronic Obstructive Pulmonary Disease (COPD) biomarker and application thereof |
US9938314B2 (en) | 2013-11-21 | 2018-04-10 | Somalogic, Inc. | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto |
-
2011
- 2011-07-11 CA CA2801110A patent/CA2801110C/en active Active
- 2011-07-11 BR BR112012032537A patent/BR112012032537B8/en active IP Right Grant
- 2011-07-11 MX MX2012014268A patent/MX2012014268A/en not_active Application Discontinuation
- 2011-07-11 AU AU2011274422A patent/AU2011274422B2/en active Active
- 2011-07-11 SG SG10201508656VA patent/SG10201508656VA/en unknown
- 2011-07-11 US US13/808,751 patent/US20130116150A1/en not_active Abandoned
- 2011-07-11 CN CN201180033907.2A patent/CN102985819B/en active Active
- 2011-07-11 SG SG2013001003A patent/SG186953A1/en unknown
- 2011-07-11 KR KR1020137000580A patent/KR101870123B1/en active IP Right Grant
- 2011-07-11 MX MX2015017251A patent/MX355020B/en unknown
- 2011-07-11 WO PCT/US2011/043595 patent/WO2012006632A2/en active Application Filing
- 2011-07-11 CN CN201510123032.5A patent/CN104777313B/en active Active
- 2011-07-11 EP EP11804482.5A patent/EP2591357A4/en not_active Withdrawn
- 2011-07-11 JP JP2013519748A patent/JP5905003B2/en active Active
- 2011-10-24 US US13/279,990 patent/US20120101002A1/en not_active Abandoned
-
2012
- 2012-11-27 IL IL223295A patent/IL223295A/en active IP Right Grant
-
2018
- 2018-05-30 US US15/993,132 patent/US11221340B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002086443A2 (en) * | 2001-04-18 | 2002-10-31 | Protein Design Labs, Inc | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
US20100070191A1 (en) * | 2008-09-09 | 2010-03-18 | Somalogic, Inc. | Lung Cancer Biomarkers and Uses Thereof |
Non-Patent Citations (1)
Title |
---|
See also references of WO2012006632A2 * |
Also Published As
Publication number | Publication date |
---|---|
MX2012014268A (en) | 2013-02-12 |
CA2801110C (en) | 2021-10-05 |
IL223295A0 (en) | 2013-02-03 |
MX355020B (en) | 2018-04-02 |
KR101870123B1 (en) | 2018-06-25 |
BR112012032537A2 (en) | 2017-05-23 |
BR112012032537B8 (en) | 2022-10-18 |
CN104777313B (en) | 2017-09-26 |
CN104777313A (en) | 2015-07-15 |
AU2011274422A1 (en) | 2012-12-20 |
US20180275143A1 (en) | 2018-09-27 |
IL223295A (en) | 2016-11-30 |
SG10201508656VA (en) | 2015-11-27 |
CN102985819B (en) | 2015-04-15 |
WO2012006632A3 (en) | 2012-05-18 |
US20120101002A1 (en) | 2012-04-26 |
CN102985819A (en) | 2013-03-20 |
WO2012006632A2 (en) | 2012-01-12 |
US20130116150A1 (en) | 2013-05-09 |
AU2011274422B2 (en) | 2016-02-11 |
US11221340B2 (en) | 2022-01-11 |
CA2801110A1 (en) | 2012-01-12 |
SG186953A1 (en) | 2013-02-28 |
JP2013532295A (en) | 2013-08-15 |
BR112012032537B1 (en) | 2021-03-02 |
JP5905003B2 (en) | 2016-04-20 |
KR20130129347A (en) | 2013-11-28 |
EP2591357A2 (en) | 2013-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL223295A0 (en) | Lung cancer biomarkers and uses thereof | |
IL252163A0 (en) | Lung cancer biomarkers and uses thereof | |
HK1256822A1 (en) | Prostate cancer ncrna and uses thereof | |
HK1204062A1 (en) | Lung cancer biomarkers and uses thereof | |
SG2014007454A (en) | Pancreatic cancer biomarkers and uses thereof | |
EP2536854A4 (en) | Personalized tumor biomarkers | |
IL225545A0 (en) | Tumor specific antibodies and uses therefor | |
EP2622104A4 (en) | Mesothelioma biomarkers and uses thereof | |
EP2534265A4 (en) | Salivary biomarkers for lung cancer detection | |
EP2625292A4 (en) | Biomarkers of cancer | |
EP2382331A4 (en) | Cancer biomarkers | |
EP2748608A4 (en) | Lung cancer tests | |
GB201016139D0 (en) | Cancer phosholipidome | |
HK1206414A1 (en) | Biomarkers for gastric cancer and uses thereof | |
EP2564200B8 (en) | Cancer biomarkers and methods of use thereof | |
EP2457092A4 (en) | Cancer biomarker and the use thereof | |
GB201021502D0 (en) | Biomarkers | |
GB201008340D0 (en) | Biomarkers | |
EP2624851A4 (en) | Moesin fragments and uses thereof | |
GB201018056D0 (en) | Biomarkers | |
GB201005561D0 (en) | Biomarkers | |
GB201001444D0 (en) | Biomarkers | |
EP2554994A4 (en) | Biomarkers | |
GB201010316D0 (en) | Biomarkers | |
GB201005456D0 (en) | Biomarkers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20121210 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1178251 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20131204 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G06F 19/20 20110101ALI20131128BHEP Ipc: G06F 19/24 20110101ALI20131128BHEP Ipc: C12Q 1/68 20060101AFI20131128BHEP Ipc: G06F 19/10 20110101ALI20131128BHEP Ipc: G01N 33/68 20060101ALI20131128BHEP Ipc: G01N 33/574 20060101ALI20131128BHEP Ipc: G06F 19/18 20110101ALI20131128BHEP |
|
17Q | First examination report despatched |
Effective date: 20141002 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20170628 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20171109 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1178251 Country of ref document: HK |